These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 382843)

  • 1. Drug interaction exposures in an ambulatory Medicaid population.
    Jinks MJ; Hansten PD; Hirschman JL
    Am J Hosp Pharm; 1979 Jul; 36(7):923-7. PubMed ID: 382843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data.
    Solberg LI; Hurley JS; Roberts MH; Nelson WW; Frost FJ; Crain AL; Gunter MJ; Young LR
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):753-9. PubMed ID: 15623265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically important potential drug-drug interactions in outpatient settings.
    Aparasu R; Baer R; Aparasu A
    Res Social Adm Pharm; 2007 Dec; 3(4):426-37. PubMed ID: 18082877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential determinants of prescribers' drug-drug interaction knowledge.
    Ko Y; Malone DC; D'Agostino JV; Skrepnek GH; Armstrong EP; Brown M; Woosley RL
    Res Social Adm Pharm; 2008 Dec; 4(4):355-66. PubMed ID: 19064242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions.
    Malone DC; Abarca J; Skrepnek GH; Murphy JE; Armstrong EP; Grizzle AJ; Rehfeld RA; Woosley RL
    Med Care; 2007 May; 45(5):456-62. PubMed ID: 17446832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.
    Gagne JJ; Maio V; Rabinowitz C
    J Clin Pharm Ther; 2008 Apr; 33(2):141-51. PubMed ID: 18315779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.
    Wong CM; Ko Y; Chan A
    Ann Pharmacother; 2008 Dec; 42(12):1737-48. PubMed ID: 19033481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons provided by prescribers when overriding drug-drug interaction alerts.
    Grizzle AJ; Mahmood MH; Ko Y; Murphy JE; Armstrong EP; Skrepnek GH; Jones WN; Schepers GP; Nichol WP; Houranieh A; Dare DC; Hoey CT; Malone DC
    Am J Manag Care; 2007 Oct; 13(10):573-8. PubMed ID: 17927462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of potential drug-drug interactions in diabetic out-patients in a tertiary care teaching hospital in Nepal.
    Dinesh KU; Subish P; Pranaya M; Shankar PR; Anil SK; Durga B
    Med J Malaysia; 2007 Oct; 62(4):294-8. PubMed ID: 18551932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population.
    Peng CC; Glassman PA; Marks IR; Fowler C; Castiglione B; Good CB
    J Manag Care Pharm; 2003; 9(6):513-22. PubMed ID: 14664659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population.
    Hamilton RA; Briceland LL; Andritz MH
    Pharmacotherapy; 1998; 18(5):1112-20. PubMed ID: 9758323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.
    Katende-Kyenda NL; Lubbe MS; Serfontein JH; Truter I
    J Clin Pharm Ther; 2008 Aug; 33(4):393-400. PubMed ID: 18613857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First 6 months of Medicaid data.
    Dobson A; Scharff J; Corder L
    Natl Med Care Util Expend Surv B; 1986 Dec; (1):1-81. PubMed ID: 10313515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.
    Seden K; Back D; Khoo S
    J Antimicrob Chemother; 2009 Jul; 64(1):5-8. PubMed ID: 19398457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
    Bachmann KA; Lewis JD
    Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placement changes and emergency department visits in the first year of foster care.
    Rubin DM; Alessandrini EA; Feudtner C; Localio AR; Hadley T
    Pediatrics; 2004 Sep; 114(3):e354-60. PubMed ID: 15342897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of drug-drug interaction software for personal digital assistants.
    Perkins NA; Murphy JE; Malone DC; Armstrong EP
    Ann Pharmacother; 2006 May; 40(5):850-5. PubMed ID: 16622155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
    Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.